UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 23, 2003

BioReliance Corporation
(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of incorporation)

0-22879	52-1541583
(Commission File Number)	(IRS Employer Identification No.)
14920 Broschart Road	20850
Rockville, Maryland	(Zip Code)
(Address of principal executive
offices)

Registrant’s telephone number, including area code: (301) 738-1000

Not Applicable
(Former name or former address, if changed since last report)

Item 9. Regulation FD Disclosure

(Provided under Item 12. Disclosure of Results of Operations and Financial Condition)

The following information is being provided under Item 12. Disclosure of Results of Operations and Financial Condition:

On July 23, 2003, the Company issued a press release announcing its earnings for the second quarter of 2003. The press release is furnished as Exhibit 99.1 hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIORELIANCE CORPORATION
By:	/s/ John L. Coker
	John L. Coker
	Vice President, Finance and
	Administrative & Chief Financial Officer

Date: July 23, 2003